Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2018 07:30 ET | Source: Otonomy, Inc.

Otonomy to Present at the J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear,...
November 08, 2017 16:12 ET | Source: Otonomy, Inc.

Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
November 08, 2017 16:05 ET | Source: Otonomy, Inc.

Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease

Achieved primary endpoint (p value = 0.029)Company plans to meet with FDA to discuss results and clinical requirements for registrationManagement will review results during third quarter conference...
November 01, 2017 16:05 ET | Source: Otonomy, Inc.

Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
September 13, 2017 07:30 ET | Source: Otonomy, Inc.

Otonomy Provides Business and Financial Update

Actions taken to reduce costs following suspension of OTIVIDEX™ developmentNon-commercial workforce reduced by one-thirdCurrent cash balance expected to fund company into 2020Review underway to...
August 03, 2017 16:12 ET | Source: Otonomy, Inc.

Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
July 27, 2017 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate Update

SAN DIEGO, July 27, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
June 22, 2017 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes

SAN DIEGO, June 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
June 20, 2017 07:30 ET | Source: Otonomy, Inc.

Otonomy to Host Key Opinion Leader Meeting for Investors on Ménière's Disease

SAN DIEGO, June 20, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
May 12, 2017 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting

SAN DIEGO, May 12, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...

Next Page keyboard_arrow_right